Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 4/20 | 0.44 |
| ▸ | S100A4 | P26447 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | IL1RN | P18510 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11392307 | 0.82 | CYP19A1 (0.50) | PLAUCYP2A6MAOAMAOBCES1 | |
| SCHEMBL11554985 | 0.78 | CYP2A6 (0.50) | CYP2A6MAOAMAOBCES1S100A4 | |
| SCHEMBL7712799 | 0.78 | CYP2A6 (0.50) | CYP2A6MAOAMAOBCES1S100A4 | |
| SCHEMBL10568813 | 0.78 | MAOA (0.50) | CYP2A6MAOAMAOBCES1S100A4 | |
| SCHEMBL30038968 | 0.76 | PLAU (1.00) | PLAUANPEPDRD2DRD3 | |
| SCHEMBL895905 | 0.76 | PLAU (1.00) | PLAUANPEPDRD2DRD3 | |
| SCHEMBL29428767 | 0.76 | PLAU (1.00) | PLAUANPEPDRD2DRD3 | |
| SCHEMBL30368725 | 0.76 | PLAU (1.00) | PLAUANPEPDRD2DRD3 | |
| SCHEMBL42952 | 0.76 | PLAU (1.00) | PLAUANPEPDRD2DRD3 | |
| SCHEMBL896147 | 0.76 | PLAU (1.00) | PLAUANPEPDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0002156-A1 | 7-Amino-5H-benzocycloheptene derivatives and their salts, a process for their preparation, their use as medicines and pharmaceutical compositions containing them | ROUSSEL-UCLAF (FR) | 1979-05-30 | — | — | EP | claimed |
| EP-2661426-B1 | PYRAZOL-4-YL CARBOXAMIDE DERIVATIVES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-08-27 | — | — | EP | disclosed |
| US-8653003-B2 | Pyrazol-4-yl carboxamide derivatives as microbiocides | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-18 | — | — | US | disclosed |
| EP-2661426-A1 | PYRAZOL-4-YL CARBOXAMIDE DERIVATIVES AS MICROBIOCIDES | Syngenta Participations AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| US-20130281505-A1 | PYRAZOL-4-YL CARBOXAMIDE DERIVATIVES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| WO-2012093100-A1 | PYRAZOL-4-YL CARBOXAMIDE DERIVATIVES AS MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| US-4814335-A | Antiviral compounds | BIOMEASURE, INCORPORATED (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0296848-A1 | Biological response modifiers, their production, and their use in therapy or in prophylaxis | BIOMEASURE, INC. (US) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281505-A1 | PYRAZOL-4-YL CARBOXAMIDE DERIVATIVES AS MICROBIOCIDES | C3AR1, CD209, CCR9 | PLAU 3719/4885CYP2A6 1541/4885MAOA 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.